{"disease":{"id":"anca-associated-vasculitis","name":"anca associated vasculitis"},"drugs":{"marketed":[{"drug_id":"avacopan","indication_name":"Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavneos","generic_name":"AVACOPAN","company_name":"Chemocentryx","drug_phase":"marketed","molecular_target":"C5a anaphylatoxin chemotactic receptor 1","drug_class":"Complement 5a Receptor Antagonist [EPC]","quality_score":62,"revenue":"400","mechanism":"Tavneos blocks the action of a chemical called C5a, which is involved in the body's inflammatory response."},{"drug_id":"ccx168","indication_name":"Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavneos","generic_name":"CCX168","company_name":"Chemocentryx","drug_phase":"discontinued","molecular_target":"C5a anaphylatoxin chemotactic receptor 1","drug_class":"Complement 5a Receptor Antagonist","quality_score":null,"revenue":null,"mechanism":"Tavneos blocks the action of a chemical called C5a, which is involved in inflammation and damage to blood vessels."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07077304","title":"EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02257866","title":"Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","has_results":false},{"nct_id":"NCT05897684","title":"Avacostar - (PASS)","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Vifor Fresenius Medical Care Renal Pharma","has_results":false},{"nct_id":"NCT05315141","title":"Multicenter Cohort Study of AAV in Hunan of China","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT05383573","title":"Pediatric ANCA Associated-vasculitis","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT02994927","title":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":331,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05416723","title":"Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P)","phase":"","overall_status":"UNKNOWN","enrollment_count":302,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT07168161","title":"BDB-001 Phase III Trial in ANCA-Associated Vasculitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT04664465","title":"PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT06462768","title":"Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis","phase":"","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT06308978","title":"A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":244,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT05716334","title":"Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator","phase":"","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT07251179","title":"Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT06611696","title":"Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Chiba University","has_results":false},{"nct_id":"NCT07010250","title":"Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":146,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07373262","title":"Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":130,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT05946564","title":"A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06868290","title":"Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04737343","title":"Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":114,"lead_sponsor_name":"Chinese SLE Treatment And Research Group","has_results":false},{"nct_id":"NCT04280601","title":"PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Christian Pagnoux","has_results":false},{"nct_id":"NCT03942887","title":"Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT05364892","title":"Biocollection of Patients With ANCA Associated Vasculitis","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT06794827","title":"Early-access Avacopan in Real-world ANCA-associated Vasculitis","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT05197842","title":"Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT06388941","title":"Iptacopan in Patients With ANCA Associated Vasculitis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":84,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07203404","title":"A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Nanjing Bioheng Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT04916704","title":"Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"University Hospital Birmingham NHS Foundation Trust","has_results":false},{"nct_id":"NCT02108860","title":"Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"University of South Florida","has_results":false},{"nct_id":"NCT02954705","title":"MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS","phase":"","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06794008","title":"BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03698071","title":"Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT07339540","title":"the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT02222155","title":"Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05965284","title":"Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Chinese SLE Treatment And Research Group","has_results":false},{"nct_id":"NCT05962840","title":"Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Chinese SLE Treatment And Research Group","has_results":false},{"nct_id":"NCT05630612","title":"ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":32,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT07389499","title":"A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Grit Biotechnology","has_results":false},{"nct_id":"NCT07151521","title":"(68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06285279","title":"The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Nanjing University School of Medicine","has_results":false},{"nct_id":"NCT06277427","title":"Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells","phase":"NA","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Lingli Dong","has_results":false},{"nct_id":"NCT06548607","title":"Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Nanjing Bioheng Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT06775912","title":"Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Nanjing Bioheng Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT06614270","title":"Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases","phase":"NA","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05859997","title":"Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":15,"lead_sponsor_name":"Bioray Laboratories","has_results":false},{"nct_id":"NCT07526350","title":"MTS109 in Patients With Refractory Autoimmune Diseases","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT07315087","title":"CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06986018","title":"Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07033299","title":"The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT06941129","title":"CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT06508346","title":"Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV","phase":"","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"The Children's Hospital of Zhejiang University School of Medicine","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}